Anzeige
+++Hot Stock!: Zwei Ozeane, zwei Tiefsee-Projekte und die Offshore-Expertise, die Tiefseebergbau erfordert+++
EQS-News

TMRW Vault® Receives CE Mark Under the European Medical Device Regulation (MDR) 06.07.2026, 15:05 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Reprotech, LLC / Key word(s): Product Launch/Miscellaneous
TMRW Vault® Receives CE Mark Under the European Medical Device Regulation (MDR)

06.07.2026 / 15:05 CET/CEST
The issuer is solely responsible for the content of this announcement.


WILMINGTON, Del., July 6, 2026 /PRNewswire/ -- Reprotech today announced that the TMRW Vault® has received CE marking as a Class IIa medical device under Regulation (EU) 2017/745, supporting commercialization in the European Union and other international markets that recognize the CE mark.

The TMRW Vault and Workstation

This achievement represents a major milestone for both the parent company, Reprotech, and the fertility industry, as the TMRW Vault combines digital chain-of-custody, advanced monitoring, and scalable cryostorage to help fertility clinics reduce risk, strengthen specimen traceability and support growth.

The TMRW Vault Freezer is a cryogenic freezer intended to provide liquid nitrogen storage for oocytes, embryos, and sperm and to facilitate the identification and traceability of specimens. The TMRW Vault Workstation allows users to transfer samples into and out of the TMRW Vault Freezer and complete orders through the Software Interface.

As fertility clinics manage rapidly growing volumes of frozen reproductive tissues, the need for safer, more scalable, and more traceable storage solutions has become increasingly important. Historically, clinics have relied on largely manual storage systems that create operational inefficiencies and increase the potential for human error.

The TMRW Vault was designed to modernize this process by combining advanced onsite cryostorage infrastructure with TMRW's proprietary ivfOS software platform, creating an integrated solution that enables digital specimen identification, continuous monitoring, real-time inventory management, and secure digital chain-of-custody that strengthens specimen traceability.

The TMRW Vault provides fertility clinics with a comprehensive onsite digital specimen management solution that includes:

  • Digital specimen management through RFID-enabled CryoBeacons and ivfOS® software that digitally verifies specimen identity and location.
  • Manual access to the Vault's tech-enabled tank, allowing embryologists to efficiently store and retrieve specimens while maintaining full digital traceability.
  • Advanced monitoring through TMRW Overwatch®, which performs thousands of daily system checks supported by expert oversight.
  • Scalable storage capacity, with a single Vault tank capable of holding as much as ten traditional dewars in approximately one-third of the footprint.
  • Seamless integration with the broader TMRW ecosystem and offsite cryostorage services.
  • Simple installation, enabling clinics to deploy the system quickly with minimal disruption.

The announcement follows the April 2026 business combination between Reprotech and TMRW Life Sciences, bringing together decades of cryostorage expertise and a U.S. national biorepository network, with next-generation digital specimen management technologies. Together with Reprotech's acquisition of IMT Matcher in June 2025, the combined organization now offers fertility clinics one of the most comprehensive ecosystems spanning specimen witnessing, digital traceability, onsite and offsite cryostorage, consent management and storage administration and billing.

About Reprotech

Reprotech is the leading provider of products and services for the safeguarding, management, and long-term storage of reproductive specimens. Reprotech's combined portfolio includes seven purpose-built biorepositories, advanced cryostorage management technologies and global digital chain-of-custody solutions. Through its TMRW, Matcher, and Cryologix family of companies, Reprotech partners with fertility centers to help reduce risk, improve traceability, streamline workflows, and safeguard specimens throughout their journey. Built on decades of experience and driven by continuous innovation, Reprotech's rigorous compliance standards and operational excellence set the benchmark for protecting specimens from clinic to cryostorage and back, ensuring customers have secure options for preserving what matters most, today and for the future. 

www.reprotech.com

Media Contact
Sarah Roberts
sroberts@reprotech.com 

Reprotech LLC

Photo - https://mma.prnewswire.com/media/3004224/The_TMRW_Vault_Workstation_Reprotech.jpg
Logo - https://mma.prnewswire.com/media/3004244/Reprotech_LLC_Logo_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/tmrw-vault-receives-ce-mark-under-the-european-medical-device-regulation-mdr-302818334.html

rt.gif?NewsItemId=EN98260&Transmission_Id=202607060902PR_NEWS_EURO_ND__EN98260&DateId=20260706


06.07.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2360954  06.07.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer